menu
    • menu
    [{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-Arterial","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RenovoRx \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Columbia University"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RenovoRx \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Oncolytic Virus Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"RenovoRx \/ Imugene"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Paulson Investment Company"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA polymerase\/RR1","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA polymerase\/RR1","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA polymerase\/RR1","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by RenovoRx

    Menu

    RenovoRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Titan Partners Group

                            Deal Size : $12.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

                            Details : The net proceeds from the financing will used to fund the clinical development of RenovoCath (gemcitabine). It is being evaluated for the treatment of locally advanced pancreatic cancer.

                            Product Name : RenovoCath

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 11, 2025

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Titan Partners Group

                            Deal Size : $12.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Titan Partners Group

                            Deal Size : $12.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

                            Details : RenovoRx intends to use the net proceeds received from the offering for the continued progression of RenovoGem (gemcitabine). It is being evaluated for Pancreatic Neoplasms.

                            Product Name : RenovoGem

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 06, 2025

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Titan Partners Group

                            Deal Size : $12.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RenovoRx Initiates Enrollment in Ph III Trial in Locally Advanced Pancreatic Cancer

                            Details : RenovoGem is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine, being investigated for treating locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Northwell Health Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RenovoRx Launches Phase III TIGeR-PaC Trial Enrollment at Northwell Health Institute

                            Details : RenovoGem is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine, being investigated for treating locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Northwell Health Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RenovoRx Enrolls First Patient in Phase III TIGeR-PaC Trial for Pancreatic Cancer

                            Details : RenovoGem is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine, being investigated for treating locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UNMC Launches Enrollment for RenovoRx’s Phase III TIGeR-PaC Clinical Trial

                            Details : RenovoGem (gemcitabine) is a drug device combination which is bein developed in patients with locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Newbridge Securities Corporation

                            Deal Size : $11.1 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

                            Details : The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 15, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Newbridge Securities Corporation

                            Deal Size : $11.1 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Newbridge Securities Corporation

                            Deal Size : $11.1 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            RenovoRx Announces $11.1 Million at Market Private Placement

                            Details : The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Newbridge Securities Corporation

                            Deal Size : $11.1 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Paulson Investment Company

                            Deal Size : $6.1 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            RenovoRx Closes $6.1 Million Private Placement

                            Details : The net proceeds will focus on the development of RenovoGem (gemcitabine), a novel oncology drug-device combination product for the treatment of locally advanced pancreatic cancer.

                            Product Name : RenovoGem

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 29, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Paulson Investment Company

                            Deal Size : $6.1 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            RenovoRx

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oncolytic Virus Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Imugene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arteria...

                            Details : The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Oncolytic Virus Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Imugene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth